Morphotek Inc.'s Research Uncovers Molecular Function of Endosialin Target of MORAb-004, Anti-Angiogenic Antibody Being Evaluated for Cancer, Neovascular Disease

EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc. today announced that a scientific paper published in the recent issue of The Proceedings of the National Academy of Sciences, sheds new light on the biological role of endosialin, also called TEM1, in promoting angiogenesis and tumor growth. Endosialin/TEM1 is a target of one of Morphotek’s therapeutic antibody programs. The article, titled “Interaction of Endosialin/TEM1 with Extra-cellular Matrix Proteins Mediates Adhesion and Cell Migration,” reports on a study performed by Morphotek researchers about the role of endosialin/TEM1 in neovascular biology.

Back to news